Sudipto Mukherjee, MD from Cleveland Clinics discusses promising novel agents that can change the treatment landscape and FLT3 and IDH1…
Browsing: Acute Lymphoblastic Leukemia
Jonathan Gerber, MD from Levine Cancer Institute discusses hopeful for the FDA approval of the IDH1 inhibitor and new generation…
The British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, had a record number of attendees, following…
At the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, we asked a number of experts…
There have been great improvements in radiotherapy (RT) services in the UK over the past 10 years; however, there is…
Radiotherapy (RT) services in England are being shaken up in a reorganization, which was a hot topic at the British…
Steve Williamson from the Northumbria Healthcare Trust, Newcastle upon Tyne, UK, and Chair of the 20 years anniversary British Oncology…
Steve Williamson from the Northumbria Healthcare Trust, Newcastle upon Tyne, UK, and Chair of the 20 years anniversary British Oncology…
Pharmacists are integral to providing and developing supportive care in cancer. In this interview, the essential roles of the pharmacist…
Supportive care for cancer is a relatively new area and is set to grow as the need for it increases.…
Supportive care for patients with cancer is becoming increasingly important, with advances in care meaning more people are surviving and…
Aaron Gerds, MD from Cleveland Clinics discusses new forms of interferon have improved side-effect profiles and pegylated interferon and ropeginterferon…
Sudipto Mukherjee, MD from Cleveland Clinics discusses personalized prediction model for Myelodysplastic Syndromes and certain mutations predict non-malignant conditions at…
Jonathan Gerber, MD from Levine Cancer Institute discusses new agents becoming available for the 1st time in decades and what…
Sudipto Mukherjee, MD from Cleveland Clinics discusses two areas that potentially cut down rehospitalizations and follow patients to be on…
Aaron Gerds, MD from Cleveland Clinics discusses patients showed symptomatic relief in Phase I Trial of Glasdegib and 35% of…
Jonathan Gerber, MD from Levine Cancer Institute discusses 9 out of 10 achieved remission with Hypomethylating agent and next phase…
Sudipto Mukherjee, MD from Cleveland Clinics discusses preliminary findings of unplanned hospital readmissions and conclusive data may identify patients to…
Aaron Gerds, MD from Cleveland Clinics discusses Phase 2 Trial of Glasdegib in myelofibrosis was not launched – due to…
Sudipto Mukherjee, MD from Cleveland Clinics discusses predicting multiple rehospitalizations after initial admission – subsets of patients who have advanced…
Jonathan Gerber, MD from Levine Cancer Institute discusses changed the strategy of chemotherapy and transplants and gentle upfront then the…
Rafael Fonseca, MD from the Mayo Clinic in Phoenix, Arizona, discusses new information for normal plasma cell biology and findings…
Masatoshi Kudo, MD from Kindai University, Japan discusses TACTICS trial demonstrates benefit with TACE plus Sorafenib in unresectable HCC at…
Masatoshi Kudo, MD from Kindai University, Japan discusses TACE new cancer region is not failure and TACE + Sorafenib should…
Masatoshi Kudo, MD from Kindai University, Japan discusses TACE + Sorafenib may change standard in HCC and if overall survival…
Rafael Fonseca, MD from the Mayo Clinic in Phoenix, Arizona, discusses real world outcomes for myeloma patients trial and phase…
Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses the Regorafenib Dose Optimization Study (ReDOS) and how a…
Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses the combination of Cobimetinib & Atezolizumab in Metastatic Colorectal…
Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses the trial Checkmate 142 Nivolumab & Ipilimumab and how…
Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses Checking for CEA in Metastatic Anal Cancer and how…
Aaron Gerds, MD from Cleveland Clinics discusses Glasdegib intended to be long-term goal for treating myelofibrosis and isolating the roots…
Aaron Gerds, MD from Cleveland Clinics discusses longer-lasting interferon being developed: Ropeginterferon and ongoing randomized trial in polycythemia vera at…
David Feltquate Head of Early Clinical Development at BRISTOL-MYERS SQUIBB discusses the the phase 1b/2 open-label study which will explore…
Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the ONC201 Safety and Advantages…
Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the ONC201 Patient Disqualifiers such…
Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses moving ONC201 from Phase 2…
Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the the Patient Enrollment for…
Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the Phase 2 ONC201 Patient…
Peter Anderson, MD, Pediatric Hematology Oncology and Blood and Marrow Transplantation of Cleveland Clinic discusses the Phase 2 ONC201 Patient…
Aaron Gerds, MD from Cleveland Clinics discusses results of Phase I trial in heavily pre-treated myelofibrosis and dysgeusia and muscle…
Mitsuo Hori, MD from Ibaraki Prefectural Central Hospital discusses results of randomized trial of ELd treatment and primary endpoint was…
Joshua Richter, MD from John Theurer Cancer Center discusses CAR-T Cell therapy as potential venue for multiple myeloma and bispecific…
Aaron Gerds, MD from Cleveland Clinics discusses phase I-II trial of Glasdegib in myelofibrosis and that Glasdegib is a Hedgehog…
Mitsuo Hori, MD from Ibaraki Prefectural Central Hospital discusses ELOQUENT-2 study in Japanese patients safety was consistent with patients in…
Joshua Richter, MD from John Theurer Cancer Center discusses GBR 1342: A bispecific T cell engager that attaches to CD38…
Dr. Jack West reviews the new FDA approval for afatinib (Gilotrif) for specific uncommon EGFR mutations, including G719X, L861Q, and…
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses FDA approval of several CAR-T Cell therapies and hope to make…
Mark Bustoros, MD from Dana-Farber Cancer Institute discusses new cancer research technologies in recent years and access new information and…